Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Recent studies from 2025 have shown that tirzepatide demonstrates superior weight loss results compared to semaglutide in head-to-head comparisons
The medication works by reducing appetite and increasing the feeling of fullness, leading to reduced food intake and ultimately supporting weight loss efforts
PMCID: PMC3212886.
[3] Orforglipron was approved for medical use in the United States in April 2026
6 Perreault, L., et al., Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
US$ 24.41
US$ 21.10
US$ 26.63
US$ 22.83
US$ 25.99
